Mylan (NSDQ:MYL) today launched its bivalirudin injection in the U.S. as a generic version of The Medicines Co.‘s (NSDQ:MDCO) Angiomax product. The medicine is a direct thrombin inhibitor designed as an anticoagulant. Mylan’s bivalirudin single-dose vial was approved by the FDA for patients with unstable angina undergoing percutaneous transluminal coronary angioplasty. The product is also indicated […]
The Medicines Co.
The pharmaceutical industry’s trade group ousted 22 companies earlier this week after it revised membership rules. The move comes as lawmakers in Washington have pressed the pharma industry about U.S. drug prices. The updated membership rules for the Pharmaceutical Research and Manufacturers of America (PhRMA) group mandates that members spend at least $200 million each year […]
The Medicines Co. (NSDQ:MDCO) and Alnylam Pharmaceuticals (NSDQ:ALNY) said today that they’ve reached a deal with the FDA over a Phase III trial for the companies’ RNA-based cholesterol-lowering drug, inclisiran. If approved, it would be the 1st RNA-interference therapy on the market. The drug is a part of a new group of drugs called PCSK9 […]